Abstract
Spatial distribution of immune cells within the tumor immune microenvironment (TIME) influences response to immunotherapy in many malignancies, but its role in neoadjuvant immunotherapy in non-small cell lung cancer (NSCLC) is not clearly established. To address this knowledge gap, we performed digital pathology analysis of tumor tissue obtained from patients with stage IIIA(N2) NSCLC undergoing neoadjuvant chemotherapy with three cycles of cisplatin/docetaxel followed by treatment with the PD-L1 antibody durvalumab in the single-arm phase II trial SAKK 16/14.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
